Skip to main content
OpenTrials
Completed

NCT Number: NCT00668343

Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo

Patient with relapsing remitting multiple sclerosis taking avonex are included in this double blind randomized control trial. Simvastatin is compared to placebo. end points of edss , total attack, new enhancing lesion and newt2 lesion in mri is evaluated as end point.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Relapsing Remitting Multiple Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Immune System Diseases Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting Nervous System Diseases

Age range

15 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Sanaz Ahmadi

Tehran, 0098, Iran

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • edss<5
  • >=1 attack in last year

Exclusion criteria

  • >2 attacks in study
  • drug complication

Treatment and study plan

simvastatin

Drug

40 mg/ day

Placebo

Drug

80 mg /day

Primary outcomes

  1. attack number

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Tehran University of Medical Sciences

Other

Registry information

Acronym: irmsrct

Important dates

Study start
2005
Primary completion
2008
Study completion
2009
First posted
Apr 29, 2008
Registry last updated
Jul 30, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.